Relapsed Primary Central Nervous System Lymphoma: Current Advances.
Relapsed Primary Central Nervous System Lymphoma: Current Advances.
复制标题
DOI:
10.3389/fonc.2021.649789
复制
发表时间:
2021
影响因子:
4.7
通讯作者:
Tian X
中科院分区:
文献类型:
--
作者:
Tao K;Wang X;Tian X
Primary central nervous system lymphoma is an invasive malignant lymphoma confined to the central nervous system. Although patients undergoing first-line treatment can achieve complete response, most of them still relapse within two years. Relapsed lymphoma is derived from occult lymphoma cells, and B cell receptor pathway activation and immune escape are the key mechanisms for the pathogenesis of PCNSL. Most relapses are in the central nervous system, a small number of relapses are isolated systemic relapses, and clinical symptoms occur early and vary. Current treatments for relapse include high-dose methotrexate rechallenge and other regimens of chemotherapy, whole-brain radiation therapy, hematopoietic stem-cell transplantation, targeted therapy and immunotherapy, which have become promising treatments. The overall prognosis of relapsed PCNSL is very poor, although it is affected by many factors. This article summarizes the mechanisms, related factors, clinical features, follow-up, treatment and prognosis of relapsed primary central nervous system lymphoma.
登录
查看更多内容
DOI:
10.1097/pai.0b013e31817bb046
发表时间:
2009-01-01
影响因子:
1.6
作者:
Chuang, Shih-Sung;Liu, Hongxiang;Lin, Li-Ching
通讯作者:
Lin, Li-Ching
影响因子:
3.9
作者:
Adachi, Jun-ichi;Mishima, Kazuhiko;Nishikawa, Ryo
通讯作者:
Nishikawa, Ryo
影响因子:
3.9
作者:
Chamberlain, Marc C.
通讯作者:
Chamberlain, Marc C.
影响因子:
9.9
作者:
Enting, RH;Demopoulos, A;Abrey, LE
通讯作者:
Abrey, LE
影响因子:
0.7
作者:
Ahmed, Zartaj;Ramanathan, Ramesh K.;Halepota, Maqbool
通讯作者:
Halepota, Maqbool